Comparing a new macular edema treatment to Eylea HD
Part of Eyes & vision clinical trials.
This study tests whether a new drug (AVT29) is as safe and effective as the standard treatment Eylea HD for people with diabetic macular edema (DME) — a condition where fluid builds up in the back of the eye due to diabetes. If you have vision loss from DME and haven't had anti-VEGF injections before, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have diabetic macular edema (DME) in at least one eye that is causing vision loss.
- Your vision in the study eye must be between 20/40 and 20/200 on an eye chart.
- You cannot have had prior treatment with anti-VEGF injections (like Lucentis or Avastin) in the study eye.
- You should not have other eye diseases that could affect your vision, besides DME.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.